Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Menarini-Venatorx

More Like This

New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection

Meiji Seika Pharma’s Nacubactam to Be Featured in 10 Presentations at ESCMID Global 2026 — Including Phase III Integral-2 Results

Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet

Allecra Therapeutics and Acino Sign Exclusive Licensing and Supply Agreement for Allecra’s Novel Antibiotic EXBLIFEP® in Gulf Cooperation Council countries and South Africa

PR Newswire associated0

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

PR Newswire associated0

Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology

TXN Systems Raises SEK 25 Million Series A to Advance First-in-Class Antibiotic

PR Newswire associated0

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand